Short answer
Pediatrix Medical Group, Inc. (MD) filed an 8-K current report with the SEC on July 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Mary Ann E. Moore departing October 31, 2026 from EVP, General Counsel, Chief Administrative Officer and Secretary roles.
Pediatrix Medical Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Mary Ann E. Moore departing October 31, 2026 from EVP, General Counsel, Chief Administrative Officer and Secretary roles
- Advisory role continues through October 31, 2026, supporting leadership transition
- Termination without cause under employment agreement, triggering specified contractual benefits
- Multiple senior legal and administrative responsibilities require succession planning oversight
Item 7.01 · Regulation FD Disclosure
- David Haddock appointed Executive Vice President, General Counsel and Secretary
- Appointment strengthens legal leadership and corporate governance oversight
- Effective July 24, 2026, with no compensation or succession terms disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pediatrix Medical Group, Inc. 8-K filings
Get the next MD 8-K as it lands
Follow MD for push alerts, or ask the research agent what this filing means.